Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV-1 Clade C gp140 protein
- Development stage
- Phase 2
- Lead developer
- Janssen Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
gp140 DP is a recombinant, trimeric HIV-1 envelope glycoprotein (gp140) derived from Clade C strains, developed by Janssen (a Johnson & Johnson company) as a protein subunit component of its heterologous prime-boost HIV vaccine regimens. The drug product is designed to present the HIV envelope in a stabilized trimeric conformation, mimicking the native viral spike to elicit broad binding and neutralizing antibody responses. It was evaluated in major clinical trials, including the Phase 3 Mosaico (HVTN 706) and Phase 2b Imbokodo (HVTN 705) studies, where it was administered as a boost following priming with adenovirus serotype 26 (Ad26) mosaic vectors. However, these large-scale efficacy trials were terminated in 2021 and 2023 after the regimens failed to provide significant protection against HIV-1 infection.
- Other names
- trimeric gp140 proteinClade C gp140HIV-1 gp140HIV1 gp140HIV 1 gp140gp140 proteingp-140 proteingp 140 protein
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on HIV-1 Clade C gp140 protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV-1 Clade C gp140 protein.